Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
1,2,3-Triazole-4-carboxamide
11%
1,6-Naphthyridines
11%
5-Amino-1
11%
Active Compounds
13%
Active Sites
7%
Acute Phase
5%
Allosteric Binding Site
11%
Amino
11%
Anti-trypanosomatid Drugs
22%
Antileishmanial
5%
Antileishmanial Activity
14%
Antitarget
5%
Antitrypanosomal Activity
11%
Antitubercular Agents
22%
Aqueous Solubility
5%
Aspergillus Fumigatus
11%
Benznidazole
12%
Benzomorpholine
5%
Binding Mode
11%
Binding Site
5%
Biochemical Assay
11%
Biochemical Characterization
11%
Biochemical Studies
7%
Brain Penetrant
11%
Brucei
7%
Carboxamide Derivatives
11%
Causative Agents
5%
Cell Behavior
5%
Cell Wall
11%
Cell-based Assay
5%
Central Nervous System
18%
Chagas Disease
59%
Chelator
11%
Chronic Phase
5%
Chronic Stage
7%
Clinical Development
5%
Compound 8
11%
Compound II
5%
Compound Library
5%
Compound Target
5%
Cryo-EM Structure
6%
Cyclin-dependent Kinase 12
11%
CYP51
11%
Cytochrome b
11%
Cytochrome bc1 Complex
5%
Cytocidal
5%
Delamanid
11%
Developable
6%
Diamino
12%
Dibasic
5%
Disease Stage
10%
Divalent
11%
Divalent Metal Cations
5%
Diversity Set
5%
Drug Candidates
7%
Drug Discovery
49%
Drug pipeline
7%
Drug Target
43%
Druggable Targets
18%
Dundee
5%
Effective Compounds
16%
Effective Treatment
6%
Electron Transport Chain
5%
Endemic Region
5%
Frontline Treatment
5%
Further Development
10%
Futures Past
11%
Genetic Characterization
11%
Genetic Studies
7%
GlaxoSmithKline
8%
Glucuronidation
5%
HERG
5%
High-content Screening
5%
High-throughput
23%
High-throughput Screening
16%
Hit Rate
11%
Human African Trypanosomiasis
43%
Human Enzymes
8%
Hydroxyl
11%
Imidazo
11%
In Vivo Activity
11%
In Vivo Efficacy
17%
Indole-2
11%
Infectious Diseases
11%
Inhibition Assay
11%
Inhibitor Discovery
11%
Inhibitor Evaluation
11%
Inhibitor Identification
11%
Intracellular Parasites
5%
Kinetochore
11%
Kinetochore Protein
8%
Kinetoplastid
36%
Kinetoplastid Parasites
21%
Lack of Information
7%
Latin America (LATAM)
5%
Latin American Populations
5%
Lead Optimization
12%
Leishmania
20%
Leishmania Donovani
51%
Leishmania Infantum
8%
Leishmania Major
7%
Leishmania Tarentolae
5%
Leishmaniasis
6%
Low Water Solubility
7%
Mechanism of Action
13%
Medicinal Chemistry
11%
Metabolic Stability
11%
Methionine
7%
Methionyl-tRNA Synthetase
22%
Mode of Action
23%
Molecular Targets
11%
Most Common Cause
5%
Mouse Model
36%
Multi-target
7%
N-myristoylation
14%
N-myristoyltransferase
65%
N-Myristoyltransferase Inhibitors
24%
Naphthyridine
22%
Neglected Diseases
11%
Neglected Tropical Diseases
6%
New Drugs
21%
New Therapeutics
10%
Nifurtimox
13%
Nitro
12%
Open Resources
11%
Oral Exposure
5%
Oral Treatment
22%
PA-824
11%
Parasite Burden
9%
Parasitic Infection
9%
Past-present
11%
Penetrant
13%
Peptide Substrate
5%
Pharmacokinetic Properties
13%
Pharmacokinetics
5%
Pharmacological Validation
11%
Phenotypic Screen
9%
Phenotypic Screening
29%
Physicochemical Properties
5%
Physiologically Relevant
5%
Potent Inhibitor
16%
Potential Treatments
22%
Preclinical Candidate
25%
Protease
6%
Protease Inhibitors
11%
Proteasome Inhibition
15%
Protein Kinase
11%
Protozoan Parasites
22%
Putative Drug Targets
9%
Pyrazole Sulfonamides
21%
Pyrazolo
22%
Pyridine Scaffold
11%
Pyrimidine
11%
Qi Site
11%
R-enantiomer
11%
Safe Treatment
9%
Scaffold Hopping
18%
Screening Campaign
7%
Sequestration
5%
Small Molecules
15%
Structure Solution
11%
Sulfonamide Antibiotics
5%
T. Brucei
21%
Target Deconvolution
5%
Therapeutic Potential
5%
Therapeutic Target
6%
Thiazolidinone
5%
Tolerability
9%
Triage
11%
Trypanosoma Brucei
79%
Trypanosoma Cruzi (T. cruzi)
76%
Trypanosomatids
25%
Visceral Leishmaniasis
90%
Whole Cell
5%
Zn2+
6%
Pharmacology, Toxicology and Pharmaceutical Science
Adenosine Triphosphate
5%
African Trypanosomiasis
46%
Amastigote
11%
Amitrole
11%
Antitarget
5%
Antitrypanosomal
11%
Benznidazole
12%
Binding Site
20%
Blood-Brain Barrier
6%
Carboxamide
22%
Chagas Disease
53%
Chelating Agent
11%
Clinical Trial
7%
Coenzyme Q - Cytochrome C Reductase
5%
Combination Therapy
6%
Cryo-Electron Microscopy
6%
Cyclic AMP Dependent Protein Kinase
5%
Cyclin Dependent Kinase
11%
Cytochrome B
11%
Delamanid
11%
Diseases
64%
Divalent
16%
Drug Discovery
49%
EC50
5%
Enzyme Inhibition
5%
Fexinidazole
8%
Hexachlorophene
14%
High-Content Screening
5%
High-Throughput Screening
10%
Infection
8%
Infectious Agent
6%
Kinetoplastida
45%
Lanosterol 14 Alpha-Demethylase
11%
Leishmania
33%
Leishmania donovani
43%
Leishmania infantum
5%
Leishmania Major
13%
Leishmania tarentolae
5%
Leishmaniasis
6%
Metal Ion
5%
Methionine
7%
Methionine Transfer RNA Ligase
22%
Molecular Target
11%
Mouse Model
42%
Naphthyridine Derivative
22%
Neglected Disease
10%
Nifurtimox
15%
Nitroreductase
6%
Parasitosis
9%
Pharmaceutical Chemistry
11%
Pharmacokinetics
17%
Phenazone
6%
Phosphotransferase
16%
Proteasome
15%
Proteasome Inhibitor
11%
Protein Kinases
11%
Proteinase
6%
Proteome
5%
Protozoon
24%
Pyrazole
20%
Pyrimidine Derivative
11%
Side Effect
11%
Structure Activity Relationship
15%
Sulfonamide
26%
Therapeutic Window
5%
Tolerability
9%
Transition Element
11%
Tropical Disease
5%
Trypanosoma Brucei
80%
Trypanosoma Cruzi
50%
Trypanosomatidae
36%
Visceral Leishmaniasis
100%
Zinc Ion
5%
Immunology and Microbiology
Amastigote
16%
Amino Acid
5%
Amino Terminal Sequence
5%
Aspergillus fumigatus
11%
Axenic
5%
Binding Site
16%
Cell Assay
5%
Cell Labeling
5%
Cell Wall
11%
Central Nervous System
5%
Chagas Disease
35%
Click Chemistry
5%
Cosmid
5%
Cryo-Electron Microscopy
6%
Crystal Structure
5%
Cytochrome
13%
EC50
5%
Enantiomer
11%
Enzyme Inhibition
5%
Epimastigote
13%
Eukaryote
6%
Infectious Agent
11%
Intracellular Transport
5%
Kinetochore
11%
Kinetoplastida
44%
Leishmania
29%
Leishmania donovani
40%
Leishmania infantum
5%
Leishmania Major
5%
Leishmania tarentolae
5%
Leishmaniasis
6%
Life Cycle Stage
5%
Methionine
7%
Mouse Model
8%
Myristylation
28%
Nuclear Magnetic Resonance Spectroscopy
5%
Parasite Load
7%
Peptides
7%
Proteasome
22%
Protein Degradation
5%
Proteomics
5%
Protozoa
16%
Qi
11%
Solution Structure
11%
Transfer RNA
22%
Trypanosoma Brucei
33%
Trypanosoma Cruzi
51%
Trypanosomatid
14%
Trypomastigote
5%
Visceral Leishmaniasis
52%
Whole Cell
7%